Eliem Therapeutics, Inc.

NASDAQ:ELYM

7.39 (USD) • At close September 6, 2024
Bedrijfsnaam Eliem Therapeutics, Inc.
Symbool ELYM
Munteenheid USD
Prijs 7.39
Beurswaarde 495,574,871
Dividendpercentage 0%
52-weken bereik 2.35 - 11.55
Industrie Biotechnology
Sector Healthcare
CEO Dr. Andrew Levin M.D., Ph.D.
Website https://www.eliemtx.com

An error occurred while fetching data.

Over Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical

Vergelijkbare Aandelen

Clearside Biomedical, Inc. logo

Clearside Biomedical, Inc.

CLSD

0.97 USD

Homology Medicines, Inc. logo

Homology Medicines, Inc.

FIXX

0.935 USD

Synlogic, Inc. logo

Synlogic, Inc.

SYBX

1.45 USD

Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd.

ENLV

1.27 USD

LENSAR, Inc. logo

LENSAR, Inc.

LNSR

4.53 USD

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

EFTR

0.04 USD

Miromatrix Medical Inc. logo

Miromatrix Medical Inc.

MIRO

3.39 USD

aTyr Pharma, Inc. logo

aTyr Pharma, Inc.

LIFE

1.9 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)